Form 4: Amicus Therapeutics Director Margaret McGlynn Reports Stock and Option Transactions

Director Margaret McGlynn reports acquisition of restricted stock units and stock options in Amicus Therapeutics.

Summary

• On June 6, 2024, Margaret McGlynn, a director of Amicus Therapeutics, reported transactions involving the company's stock.
• McGlynn acquired 11,847 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0.00, which will vest in full on the one-year anniversary of the grant date.
• One RSU is equivalent to one share of Amicus common stock.
• Additionally, McGlynn acquired 42,467 stock options with an exercise price of $10.27, which will vest and become exercisable on the one-year anniversary of the grant date and expire on June 6, 2034.
• Following these transactions, McGlynn beneficially owns 71,136 shares of common stock and 42,467 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reporting insider transactions. The acquisition of shares and options could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions can provide insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Amicus Therapeutics.

Key Dates